Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DOXORUBICIN Cause Transplant failure? 31 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 31 reports of Transplant failure have been filed in association with DOXORUBICIN (Doxorubicin Hydrochloride). This represents 0.0% of all adverse event reports for DOXORUBICIN.

31
Reports of Transplant failure with DOXORUBICIN
0.0%
of all DOXORUBICIN reports
27
Deaths
2
Hospitalizations

How Dangerous Is Transplant failure From DOXORUBICIN?

Of the 31 reports, 27 (87.1%) resulted in death, 2 (6.5%) required hospitalization, and 1 (3.2%) were considered life-threatening.

Is Transplant failure Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for DOXORUBICIN. However, 31 reports have been filed with the FAERS database.

What Other Side Effects Does DOXORUBICIN Cause?

Febrile neutropenia (8,844) Off label use (7,858) Disease progression (6,165) Neutropenia (5,891) Drug ineffective (4,598) Pyrexia (3,697) Thrombocytopenia (3,638) Anaemia (3,601) Product use in unapproved indication (3,502) Nausea (2,925)

What Other Drugs Cause Transplant failure?

TACROLIMUS (559) MYCOPHENOLATE MOFETIL (436) CYCLOPHOSPHAMIDE (221) FLUDARABINE (218) PREDNISONE (182) CYCLOSPORINE (180) PREDNISOLONE (172) BUSULFAN (147) LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN (113) AUTOLOGOUS CULTURED CHONDROCYTES (108)

Which DOXORUBICIN Alternatives Have Lower Transplant failure Risk?

DOXORUBICIN vs DOXYCYCLINE DOXORUBICIN vs DOXYCYCLINE HYCLATE DOXORUBICIN vs DOXYCYCLINE\DOXYCYCLINE HYCLATE DOXORUBICIN vs DOXYLAMINE DOXORUBICIN vs DOXYLAMINE\PYRIDOXINE

Related Pages

DOXORUBICIN Full Profile All Transplant failure Reports All Drugs Causing Transplant failure DOXORUBICIN Demographics